Multiple Myeloma

>

Latest News

Developers designed ISB 2001 to target BCMA and CD38 expressed on myeloma cells as well as CD3 on T cells.
FDA Gives Fast Track Designation to ISB 2001 in Relapsed/Refractory Myeloma

May 7th 2025

Phase 1 data demonstrate enduring responses with ISB 2001 among patients with relapsed/refractory multiple myeloma.

"[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation," according to the study authors.
Salvage Isatuximab Combo Elicits Efficacy in Lenalidomide-Relapsed Myeloma

May 3rd 2025

The EU approval was based on results from the phase 1/2 LINKER-MM1 trial assessing the efficacy of linvoseltamab in relapsed/refractory multiple myeloma.
Linvoseltamab Receives EU Approval for Relapsed/Refractory Multiple Myeloma

April 30th 2025

“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.
Mortality, Adverse Outcome Odds Higher in Multiple Myeloma PEM Population

April 28th 2025

Treatment with daratumumab-based combination therapies may drive minimal residual disease conversion rates in patients with newly diagnosed multiple myeloma.
Assessing CD38 Monoclonal Antibody-Based Regimens in NDMM

April 27th 2025

More News